Month: April 2026

Release – Townsquare Announces Conference Call to Discuss First Quarter 2026 Results

Posted on by [email protected]

Research News and Market Data on TSQ

Released : 04/06/2026

PURCHASE, N.Y., April 06, 2026 (GLOBE NEWSWIRE) — Townsquare Media, Inc. (NYSE: TSQ) (“Townsquare” or the “Company”) announced today that it will release first quarter 2026 financial results before the market opens on Monday, May 11, 2026. The Company will host a conference call to discuss certain first quarter 2026 financial results on Monday, May 11, 2026 at 8:00 a.m. Eastern Time.

The conference call dial-in number is 1-800-717-1738 (U.S. & Canada) or 1-646-307-1865 (International) and the conference ID is “Townsquare.” A live webcast of the conference call as well as the press release disclosing the Company’s results will be available on the investor relations page of the Company’s website at www.townsquaremedia.com.

A telephone replay of the conference call will be available through May 18, 2026. To access the replay, please dial 1-844-512-2921 (U.S. & Canada) or 1-412-317-6671 (International) and enter confirmation code 1199273. A web-based archive of the conference call will also be available on the investor relations page of the Company’s website.

About Townsquare Media, Inc.
Townsquare is a community-focused digital and broadcast media and digital marketing solutions company principally focused outside the top 50 markets in the U.S.Townsquare Ignite, our robust digital advertising division, specializes in helping businesses of all sizes connect with their target audience through data-driven, results based strategies, by utilizing a) our proprietary digital programmatic advertising technology stack with an in-house demand and data management platform and b) our owned and operated portfolio of more than 400 local news and entertainment websites and mobile apps along with a network of leading national music and entertainment brands, collecting valuable first party data. Townsquare Interactive, our subscription digital marketing services business, partners with SMBs to help manage their digital presence by providing a SAAS business management platform, website design, creation and hosting, search engine optimization and other digital services. And through our portfolio of local radio stations strategically situated outside the Top 50 markets in the United States, we provide effective advertising solutions for our clients and relevant local content for our audiences. For more information, please visit www.townsquaremedia.com, www.townsquareinteractive.com, and www.townsquareignite.com.

Investor Relations
Claire Yenicay        
(203) 900-5555
[email protected]

Primary Logo

Source: Townsquare Media Inc.

Release – NeuroSense Granted Brazilian Patent Covering PrimeC Composition

Posted on by [email protected]

Research News and Market Data on NRSN

  • Patent Protection Through October 2042
  • Follows prior patent grants in the U.S. and Australia
  • Further strengthens NeuroSense’s global intellectual property portfolio

CAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Brazilian Patent and Trademark Office (INPI) has granted Brazilian Patent No. BR 112024007727-6, entitled “Compositions Comprising Ciprofloxacin and Celecoxib.”

The granted Brazilian patent, following prior approval of the corresponding U.S. patent (12,097,185) and Australian patent (2022370513), provides protection for NeuroSense’s proprietary PrimeC composition in Brazil and extends patent coverage through October 2042, further strengthening the Company’s global intellectual property estate and supporting the long-term development and potential commercialization of PrimeC in ALS, Alzheimer’s disease and additional neurodegenerative indications.

“This patent grant further reinforces the strength and durability of our intellectual property strategy around PrimeC,” said Alon Ben-Noon, Chief Executive Officer of NeuroSense. “Securing composition-of-matter protection in Brazil is another important step in expanding our global IP footprint as we advance PrimeC toward pivotal development and potential commercialization.”

PrimeC is a proprietary fixed-dose oral therapy combining ciprofloxacin and celecoxib in a synchronized, extended-release formulation specifically targeted to deliver both agents in a coordinated manner – a key differentiator versus simple co-administration. The formulation is designed to enable consistent exposure across multiple disease pathways implicated in ALS, including neuroinflammation, iron dysregulation, and miRNA dysregulation, supporting a multi-target disease-modifying approach.

We are preparing for initiation of a Phase 3 pivotal clinical trial for PrimeC in ALS (PARAGON), following positive Phase 2b PARADIGM results and clearance from the FDA.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

About Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting more than 30 million people globally. AD is characterized by memory loss, cognitive decline, and behavioral changes, and currently has no cure. Existing therapies provide only limited symptomatic relief, leaving a significant unmet need for disease-modifying treatments that can slow or halt progression. Given the complexity of AD, approaches that target multiple disease mechanisms simultaneously, such as PrimeC, hold potential to deliver meaningful therapeutic advances for patients and their families.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding PrimeC pivotal trial. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk that we do not complete in a timely fashion the PrimeC pivotal trial, and that the single pivotal trial will not be sufficient to support a New Drug Application submission; uncertainty regarding the timing of regulatory filings, meetings and regulatory decisions; outcomes and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; the going concern reference in our financial statements and our need for substantial additional financing to achieve our goals; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

For further information: For further information: [email protected], +972 (0)9 799 6183

Release – The Oncology Institute Names Minh Merchant Chief Legal Officer

Posted on by [email protected]

Research News and Market Data on TOI

Apr 06, 2026

PDF Version

CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Ms. Merchant will oversee legal, regulatory, compliance and privacy functions as TOI continues to scale. This role will be essential in enabling the company to continue its growth trajectory while further enhancing its mission to be a trusted healthcare partner to oncology patients and payors.

Ms. Merchant has more than two decades of experience advising public and private healthcare organizations, including significant experience in transactional, regulatory and compliance matters. She previously served as general counsel at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson, and holds a JD from UCLA School of Law.

“We are excited to welcome Minh to TOI as our Chief Legal Officer,” said Daniel Virnich, MD, CEO of The Oncology Institute. “As our footprint and care model continue to grow, she brings the depth of experience to help TOI continue operate as a compliant and secure national oncology platform.”

“I’m thrilled at the opportunity to join TOI at this important juncture in the organization’s growth as a public company,” commented Ms. Merchant. “The organization’s mission to provide better access and affordability to cancer care is inspiring and I feel that I’m well positioned to help TOI continue its successful navigation of the rapidly evolving healthcare legal and regulatory environment.”

About The Oncology Institute (www.theoncologyinstitute.com):
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.

Media
The Oncology Institute, Inc.
[email protected]

Investors
ICR Healthcare
[email protected]

Release – Snail Games Expands Portfolio with Publishing Agreement for Co-op Party Action Title Dead Party

Posted on by [email protected]

Research News and Market Data on SNAL

April 6, 2026 at 8:30 AM EDT

PDF Version

CULVER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, announced it has secured global publishing rights from Radiation Blue for Dead Party, a co-op party action game that blends base defense mechanics with fast-paced multiplayer gameplay. The addition of Dead Party reinforces Snail Games’ strategic focus on diversifying its portfolio across accessible, socially driven gaming experiences.

Dead Party challenges players to work together in teams of up to four to defend against waves of alien-driven zombies using creative traps, environmental strategy, and music-powered combat. The title features both a narrative-driven Story Mode and a highly replayable Arcade Mode, designed to engage a broad audience across cooperative and casual gameplay segments.

The partnership underscores Snail Games’ continued commitment to balancing its portfolio across genres, combining its established presence in survival and sandbox titles with emerging opportunities in cooperative and session-based gameplay. By investing in titles with strong multiplayer engagement loops and scalable content models, the Company aims to enhance long-term player retention.

With its emphasis on cooperative gameplay, humor-driven design, and replayability, Dead Party is positioned to appeal to a wide demographic of players, including both core and casual audiences. The title’s flexible game modes and social-first design align with current market trends favoring shared experiences and creator-friendly content.

Players can wishlist Dead Party on Steam today to stay updated on future reveals, release timing, and upcoming content. Dead Party will also be coming to Xbox Series X|S and PlayStation 5 consoles upon release.

Watch Dead Party’s Announcement Trailer

For creators interested in collaborations please reach out to [email protected]

Dead Party press kit

About Radiation Blue

We are an independent developer located near Freiburg, Germany. We enjoy working in a small, efficient and creative group. Prior to Dead Party, we worked on different projects and shipped Genesis Alpha One, Hitman Blood Money, Velvet Assassin, RiME, Galaxy on Fire, Gothic, Neocron, Dead Block, Das Schwarze Auge1 & 2, The Settlers among other things.

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/

Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding diversifying Snail Games’ portfolio across accessible, socially driven gaming experiences, balancing Snail Games’ portfolio across genres, combining Snail Games’ established presence in survival and sandbox titles with emerging opportunities in cooperative and session-based gameplay, enhancing long-term player retention by investing in titles with strong multiplayer engagement loops and scalable content models and Dead Party appealing to a wide demographic of players, including both core and casual audiences. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, acceptance of our titles in the marketplace and the successful development, marketing or sale of our titles and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
[email protected]

Release – NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

Posted on by [email protected]

Research News and Market Data on NRSN

  • Notifications have no immediate effect on the listing or trading of the Company’s securities on Nasdaq
  • Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements
  • The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value

CAMBRIDGE, Mass., April 3, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company developing treatments for severe neurodegenerative diseases, today announced that it received two notification letters from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on April 2, 2026, indicating that the Company is not in compliance with certain continued listing requirements of The Nasdaq Capital Market.

The first notification letter indicated that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share, since the closing bid price of the Company’s ordinary shares was below $1.00 per share for 30 consecutive business days, from February 18, 2026 through March 31, 2026.

The second notification letter indicated that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires listed securities to maintain a minimum market value of listed securities (“MVLS”) of $35 million, since the Company’s MVLS was below $35 million for 30 consecutive business days over the same period.

These notifications have no immediate effect on the listing or trading of the Company’s securities on Nasdaq. The Company’s ordinary shares and warrants will continue to trade on The Nasdaq Capital Market under the symbols “NRSN” and “NRSNW,” respectively.

In accordance with Nasdaq Listing Rules, the Company has a compliance period of 180 calendar days, or until September 29, 2026, to regain compliance with both the minimum bid price requirement and the MVLS requirement. To regain compliance, the Company’s ordinary shares must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, and the Company’s MVLS must close at $35 million or more for a minimum of 10 consecutive business days, in each case subject to Nasdaq’s discretion.

The Company continues to actively monitor the closing bid price of its ordinary shares and its MVLS and is evaluating available actions to regain compliance with Nasdaq’s continued listing requirements, with a clear focus on initiatives that support and enhance long-term shareholder value. 

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, reporting of data, meetings and regulatory decisions. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the timing of regulatory filings, meetings and regulatory decisions; outcomes and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

For further information: For further information: [email protected], +972 (0)9 799 6183

Cocrystal Pharma (COCP) – CDI-988 Receives Fast Track Designation, Raising Its Profile

Posted on by cpatches


Monday, April 06, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Cocrystal Receives Fast Track Designation. CDI-988 has been awarded Fast Track Designation by the FDA, a designation given to drugs that treat serious conditions with no effective treatments. It is intended to streamline the clinical development and  shorten regulatory review for products treating unmet medical needs. The designation should save Cocrystal time and clinical expenses, as well as give recognition to CDI-988 as a meaningful new vaccine for the prevention and treatment of norovirus.

Fast Track Designation Is Intended To Help Drug Development. The FDA’s Fast Track designation has several benefits to help companies develop drugs for unmet medical needs. During the development process, Cocrystal can have more frequent communications with the FDA to obtain its guidance throughout the process.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Ocugen (OCGN) – Dosing Completed Early In The OCU410ST Phase 2/3 GARDian Trial

Posted on by cpatches


Monday, April 06, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

OCU410ST Treatment Has Been Completed Ahead Of Schedule. The Stargardt disease Phase 2/3 Trial testing OCU410ST has completed patient enrollment and treatment in 9 months, beating our estimated time of 12 months. The trial enrolled 63 patients, with an interim analysis planned when 24 patients have completed the follow-up evaluation at month 8 after treatment. This is expected to be announced in 3Q26. The primary endpoint for the BLA is based on the 1-year evaluation, which should occur around 1Q27.

OCU410ST Restores Pathways To Prevent Blindness. OCU410ST (AAV5-hRORA) uses Ocugen’s proprietary modifier gene technology to deliver hRORA, a gene that controls pathways that can lead to macular degeneration in Stargardt disease. OCU410ST is a single subretinal injection that leads to durable gene expression, restoring homeostasis in those pathways, preventing death of cells in the retina, and preserving visual function.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Nutriband (NTRB) – First Marketing Partnership Expands Territory and Brings A Product Approval

Posted on by cpatches


Monday, April 06, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Marketing Partnership Covering Costa Rica Brings First Success. In February, Nutriband signed an agreement with Costa Rica’s Innomedica CCB, making it the territory’s exclusive distributor of Nutriband products and AVERSA Fentanyl upon approval. Shortly afterward, the Costa Rican Ministry of Health approved the Nutriband kinesiology tapes for import and sale, making them the first Nutriband products that Innomedica has guided through local regulatory approvals. It plans to begin marketing efforts for the kinesiology tapes, the mosquito repellent patch, and begin AVERSA Fentanyl patch marketing in anticipation of approval.

Moving Forward With AVERSA Fentanyl. Nutriband is preparing to start its clinical trial testing to test the abuse deterrence of its proprietary AVERSA Fentanyl patch. This trial will test a generic fentanyl patch against the AVERSA Fentanyl patch to determine if substance abusers can obtain the drug without activating the with aversive chemicals. We expect the trial to begin around mid-FY2026.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Neurocrine to Acquire Soleno Therapeutics, Expanding Rare Disease and Endocrinology Portfolio

Posted on by cpatches

Neurocrine Biosciences (NASDAQ: NBIX) announced it has entered into a definitive agreement to acquire Soleno Therapeutics (NASDAQ: SLNO) for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion. The offer reflects a premium of roughly 34% to Soleno’s April 2 closing price and 51% to its 30-day volume-weighted average price.

The acquisition adds VYKAT™ XR (diazoxide choline), the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome (PWS), to Neurocrine’s growing portfolio of first-in-class therapies. The transaction is expected to close within 90 days, subject to customary conditions and regulatory approvals.

Expanding a High-Growth Portfolio

With the addition of VYKAT XR, Neurocrine will have three marketed, first-in-class therapies:

  • INGREZZA® (valbenazine) – a VMAT2 inhibitor for tardive dyskinesia and Huntington’s chorea, generating $2.51 billion in 2025 revenue
  • CRENESSITY® (crinecerfont) – approved in late 2024 for congenital adrenal hyperplasia, with $301 million in 2025 revenue
  • VYKAT XR – approved in March 2025 for PWS, delivering $190 million in 2025 revenue

Together, these therapies position Neurocrine for sustained revenue growth and portfolio diversification through the end of the decade.

A Transformative Therapy in a High-Unmet-Need Market

VYKAT XR addresses hyperphagia, the defining and life-threatening symptom of Prader-Willi syndrome, a rare genetic disorder affecting approximately 10,000 patients in the U.S. The condition leads to persistent hunger, compulsive food-seeking behavior, and significant metabolic and behavioral challenges.

Since its U.S. launch in the second quarter of 2025, VYKAT XR has seen strong early adoption, including $92 million in fourth-quarter revenue alone. The therapy is expected to generate approximately $450 million in revenue this year and is supported by intellectual property protection extending into the mid-2040s.

Cocrystal Pharma (COCP) – CDI-988 Receives Fast Track Designation, Raising Its Profile
Ocugen (OCGN) – Dosing Completed Early In The OCU410ST Phase 2/3 GARDian Trial
Nutriband (NTRB) – First Marketing Partnership Expands Territory and Brings A Product Approval

“This transaction will advance Neurocrine’s mission to deliver life-changing treatments while accelerating our revenue growth and portfolio diversification strategy,” said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine. “We look forward to expanding VYKAT XR’s reach and strengthening our leadership in delivering transformative medicines.”

Strategic Entry Into Metabolic Disease

The acquisition also marks Neurocrine’s entry into metabolic disorders, complementing its existing endocrinology focus. This comes as the broader market sees heightened competition following the success of GLP-1 drugs such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy.

Neurocrine believes its expertise in CRF1 receptor antagonists and endocrine pathways may offer differentiated approaches, particularly in addressing concerns around muscle loss associated with current obesity treatments.

Analysts suggest the deal provides a more immediate and practical pathway into metabolic disease compared to earlier-stage internal programs, which still face regulatory and competitive hurdles.

Financial and Transaction Details

Under the agreement, Neurocrine will launch a tender offer to acquire all outstanding Soleno shares. Following completion, a subsidiary will merge with Soleno, converting remaining shares into the same $53.00 per share cash consideration.

The transaction will be funded through a combination of cash on hand and a modest amount of pre-payable debt. Notably, the deal is not subject to financing conditions.

Both companies’ boards have approved the transaction.

Market Reaction

Shares of Soleno surged approximately 34.5% in premarket trading following the announcement, reflecting investor confidence in the deal’s premium and strategic rationale.

Outlook

The acquisition is expected to:

  • Strengthen Neurocrine’s leadership in rare disease and endocrinology
  • Expand its commercial footprint with a durable, first-in-class therapy
  • Enhance long-term revenue visibility and growth profile
  • Deliver operational synergies through integration

With VYKAT XR as a foundational asset and continued pipeline progress, Neurocrine is positioning itself for sustained value creation in both rare disease and metabolic markets.

Markets on Edge as Trump Iran Deadline Nears

Posted on by cpatches

Markets at a Glance

  • Stocks: Modestly higher, but trading cautiously
  • Oil: Above $110, swinging on Iran headlines
  • Bonds: Yields steady as investors weigh inflation risk
  • Volatility: Elevated ahead of Trump’s deadline

Wall Street traded cautiously Monday while oil prices swung sharply as geopolitical tensions escalated, with President Donald Trump intensifying threats against Iran ahead of a Tuesday 8 p.m. ET deadline to reopen the Strait of Hormuz.

The hesitation comes after a strong rebound last week, when the S&P 500 rose 3.4%, snapping a five-week losing streak. That momentum is now being tested by rising uncertainty around global energy flows and the potential for a significant escalation in the Middle East.

Ceasefire Talks Falter

Diplomatic efforts remain fluid but increasingly strained. Reports indicate the U.S., Iran, and regional mediators have discussed a 45-day ceasefire and broader proposals that could reopen the Strait. However, Iran has rejected a temporary ceasefire, calling instead for a permanent end to the war with guarantees against future attacks.

Trump acknowledged that Iran had made a “significant step” in negotiations but said it was “not good enough,” reinforcing that the U.S. is prepared to act if its demands are not met.

Trump Signals Readiness for Rapid Strikes

During a Monday press conference, Trump outlined the potential scale and speed of U.S. military action, stating that American forces could destroy Iran’s bridges and power infrastructure within hours.

“We have a plan… where every bridge in Iran will be decimated by 12 o’clock tomorrow night,” Trump said, adding that power plants would be “burning, exploding and never to be used again.”

He also dismissed concerns about potential violations of international law, saying he is “not at all” worried about accusations of war crimes, even as the United Nations warned that attacks on civilian infrastructure could violate international law.

Trump also criticized NATO allies and key Pacific partners—including Japan, South Korea, and Australia—for not supporting U.S. efforts to reopen the Strait of Hormuz.

Oil Becomes the Market’s Pressure Point

Markets are reacting primarily through energy. The Strait of Hormuz is one of the world’s most critical oil chokepoints, and any disruption to flows can quickly tighten global supply and push prices higher.

Oil continued trading above $110 per barrel, with intraday swings reflecting the push and pull between:

  • Hopes for a diplomatic resolution
  • Rising risk of U.S. strikes on Iranian infrastructure
  • Continued attacks on energy-related facilities

Recent strikes, including reported attacks on Iran’s South Pars petrochemical complex, highlight the growing risk that energy infrastructure could become a central target in the conflict.

Conflict Expands, Timeline Unclear

The situation on the ground continues to intensify. Israeli and U.S. forces carried out additional strikes on Iran Monday, while Iran responded with missile attacks targeting Israel and Gulf Arab states. Senior Iranian military officials were also reportedly killed in the latest round of fighting.

Israel’s defense leadership has signaled preparations for weeks of continued conflict, suggesting tensions—and market volatility—may persist beyond the immediate deadline.

Meanwhile, Trump’s timeline for ending the war remains uncertain. While he previously suggested a roughly six-week conflict, shifting objectives and ongoing escalation have made the endgame increasingly unclear.

Investor Takeaway

Markets have shifted into a headline-driven environment, where geopolitical developments—not economic data—are dictating direction.

  • Best case: A deal reopens the Strait, easing oil prices and supporting equities
  • Risk case: Missed deadline triggers U.S. strikes, sending oil higher and pressuring stocks
  • Base case: Continued volatility as negotiations and escalation unfold in parallel

For now, oil remains the key signal. As long as crude prices stay elevated and reactive to headlines, broader market sentiment is likely to remain cautious despite last week’s rebound.

Release – GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026

Posted on by [email protected]

Research News and Market Data on GOVX

MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen

ATLANTA, GA, April 2, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today highlighted preclinical data presented at the World Vaccine Congress Washington 2026 supporting the potential for a single-dose Modified Vaccinia Ankara (MVA)-based mpox vaccine. The data demonstrate that a novel MVA vaccine construct incorporating an immunomodulatory peptide (“MVA-X”) achieved protective efficacy, comparable to the traditional two-dose MVA regimen, in a murine orthopoxvirus challenge model.

  • The presentation, titled “Next-Generation MVA Mpox Vaccines: Harnessing an Immunomodulatory Peptide for Single-Dose Efficacy,” was delivered by Heather Koehler, Ph.D., of Washington State University, during the Immune Profiling track on April 1, 2026.
  • Single-dose efficacy: the MVA-X vaccine construct achieved complete protection comparable to a two-dose MVA vaccine regimen in a lethal orthopox challenge model, while a single-administration of MVA showed only partial protection.
  • Durable protection: Protective immunity was maintained through Day 150 post-vaccination, with 100% survival observed in both MVA-X (single-dose) and two-dose MVA groups.
  • Robust viral control: MVA-X demonstrated significant reduction in lung viral burden, comparable to the two-dose MVA regimen.
  • Improved clinical outcomes: MVA-X vaccinated animals exhibited minimal weight loss, reduced disease severity, and preserved lung structure.
  • T cell-driven immunity: Protection in MVA-X vaccinated animals was independent of neutralizing antibodies, supported by enhanced CD4+ and CD8+ T cell responses.

Mechanistic Innovation

The MVA-X construct incorporates a peptide designed to transiently modulate the PD-1 immune checkpoint pathway, enhancing T cell activation and durability of immune response during vaccination.

This approach enables:

  • Stronger and more sustained T cell responses
  • Enhanced immune memory
  • Potential for durable protection with fewer doses

This represents a novel application of immune checkpoint modulation within vaccine design.

“These findings provide an important proof-of-concept that the performance of MVA-based vaccines can be enhanced to potentially achieve single-dose protection,” said Mark Newman, Ph.D., Chief Scientific Officer of GeoVax. “The preclinical data demonstrates a clear biological signal that supports continued exploration of immune-enhanced MVA constructs.”

David A. Dodd, Chairman and Chief Executive Officer of GeoVax, added: “As mpox continues to emerge as a recurring global health and biodefense concern, the need for vaccines that are both durable and rapidly deployable has become increasingly clear. An MVA-X vaccine may offer the opportunity to meaningfully improve vaccination coverage, compliance, and outbreak response – particularly in resource-constrained or high-risk environments.”

Dodd further noted: “These results reinforce the strength and flexibility of the MVA platform that underpins our GEO-MVA program. With a defined regulatory pathway in place and preparations underway to initiate a Phase 3 immune bridging study, GeoVax is focused on advancing an MVA vaccine designed to expand global supply, support public health preparedness, and address the limitations of existing options.”

Strategic Context

  • Supports Single-Dose Strategy for MVA-based immunization: Potential to simplify vaccination and improve real-world deployment
  • Aligns with Market Need: Potential to addresses drawbacks of current mpox vaccines, including multi-dose requirements and durability

About the Study

The study evaluated MVA-X, an MVA-based vaccine incorporating an immunomodulatory peptide sequence designed to enhance T cell responses. In murine models, animals were challenged with high-dose vaccinia virus at multiple timepoints (Days 55, 90, and 150), with outcomes including survival, viral load, clinical pathology, and immune response.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax’s broader pipeline includes the development of GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised and other patient populations. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected]

Release – SEGG Media Expands Soccerex Partnership, Positioning Sports.com at Center of Global Football Deal Ecosystem

Posted on by [email protected]

Research News and Market Data on SEGG

April 2, 2026

PDF Version

Headline Partnership Drives Access to Media, Sponsorship and Investment Opportunities

FORT WORTH, Texas, April 02, 2026 (GLOBE NEWSWIRE) — Sports Entertainment Gaming Global Corporation (NASDAQ: SEGG, LTRYW) (the “Company” or “SEGG Media”), the global sports, entertainment, and gaming group, today announced the expansion of its partnership with Soccerex, becoming the official headline sponsor across all global Soccerex events in 2026 and 2027. The partnership spans across Europe, North America, and the Middle East, and will integrate the Sports.com brand into Soccerex’s year-round platform engaging hundreds of industry stakeholders. The timing of this partnership with Soccerex aligns with SEGG Media’s near term objective to complete the acquisition of a European football club.

This partnership provides SEGG Media with direct access to a global pipeline of commercial opportunities across media rights, sponsorship, content distribution, and strategic partnerships. Soccerex events convene decision-makers responsible for billions in annual football-related investment, creating a structured environment to originate proprietary deal flow, evaluate opportunities, and execute revenue-generating transactions aligned with the Company’s growth strategy for the Sports.com brand. The Company expects this partnership to serve as a catalyst for revenue-generating partnerships and strategic transactions across its Sports.com platform.

For nearly 30 years, Soccerex has brought together clubs, leagues, federations, investors, and commercial partners from across the game, creating a trusted meeting point for the conversations, relationships, and opportunities that shape the future of football.

The collaboration will give the Company direct access to senior decision-makers responsible for more than $1 billion in annual football-related commercial spend, while also creating opportunities to contribute to industry dialogue, participate in structured commercial introductions through Soccerex’s Deal Network, and build year-round visibility across Soccerex’s expanding media and digital ecosystem.

Through this partnership, Sports.com will leverage Soccerex’s ecosystem to accelerate:

  • Content distribution partnerships;
  • Sponsorship and brand integration opportunities;
  • Strategic investments and acquisitions within football; and
  • Development of Sports.com’s global media and streaming footprint.

Garrett Armando Navia, CEO, Soccerex, commented: “Sports.com isn’t just partnering with Soccerex – they’re stepping into the center of the global football ecosystem at a time when the industry is evolving faster than ever.

“For nearly three decades, Soccerex has been the platform where the most important relationships in football are built and where the business of the game moves forward. This partnership brings together two platforms aligned in vision – one focused on being the connective core of the global football economy and the other focused on engagement and innovation.

“Together, we are creating something bigger than events – a year-round system that drives real outcomes, unlocks opportunity, and shapes the next era of the football economy.”

The relationship is structured to generate measurable commercial outcomes by positioning Sports.com within the flow of influence, investment, and innovation across the global football ecosystem. By aligning with Soccerex’s established reach to key industry stakeholders and powerbrokers, the Company will play a central role in creating a more connected, commercially active, and globally relevant football business environment.  

Marc Bircham, SEGG Media Chairman added: “For SEGG Media, the timing of this partnership could not be more perfect. As things heat up for the Company in its pursuit of acquiring a European football club, Soccerex is an ideal partner with access to the most trusted and influential stakeholders in the global football business. There is no other platform that convenes this level of decision-making power across the sport.

“We also view this partnership as an execution platform designed to convert access into measurable commercial outcomes and accelerate the monetization of the Sports.com brand.

“This is a partnership built on scale, credibility, and shared ambition – and we are proud to be part of Soccerex’s next chapter as it continues to define the future of football.”

The Company will approach this partnership with a disciplined focus on converting access into measurable outcomes aligned with its broader capital allocation and growth strategy, and expects to provide updates on commercial partnerships, strategic initiatives, and transaction activity arising from this collaboration.

This partnership represents a strategic step in embedding Sports.com within the global football economy and advancing the Company’s broader acquisition-led and revenue-focused growth strategy.

About Soccerex
Soccerex is the global football business platform — and for 30 years, the industry’s most trusted meeting place. Operating at the intersection of relationships, capital, deal-making and innovation, Soccerex convenes the most influential stakeholders in football through world-class events, year-round digital engagement, and structured commercial platforms.

About SEGG Media Corporation
SEGG Media (Nasdaq: SEGG, LTRYW) is a global sports, entertainment and gaming group operating a portfolio of digital assets including Sports.com, Concerts.com, TicketStub.com, and Lottery.com. Focused on immersive fan engagement, ethical gaming and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love.

For additional information, visit www.seggmedia.com or contact media relations [email protected]

Important Notice Regarding Forward-Looking Statements 

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “initiatives,” “continue,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, any future findings from ongoing review of the Company’s internal accounting controls, additional examination of the preliminary conclusions of such review, the Company’s ability to secure additional capital resources, the Company’s ability to continue as a going concern, the Company’s ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company’s ability to regain compliance with the Bid Price Requirement, the Company’s ability to regain compliance with Nasdaq Listing Rules, the Company’s ability to become current with its SEC reports, and those additional risks and uncertainties discussed under the heading “Risk Factors” in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.

This press release was published by a CLEAR® Verified individual.

For additional information, contact media relations at [email protected].

Release – CVG Announces Sale-Leaseback Transaction to Improve Balance Sheet Strength

Posted on by [email protected]

Research News and Market Data on CVGI

April 2, 2026

NEW ALBANY, Ohio, April 02, 2026 (GLOBE NEWSWIRE) — Commercial Vehicle Group (the “Company or “CVG”) (NASDAQ: CVGI), a diversified industrial products and services company, today announced that it has completed a sale-leaseback transaction for its manufacturing facility in Vonore, Tennessee, which generated $16 million in proceeds. The Company used the net proceeds from the transaction to prepay a portion of its existing term loan facility, thereby reducing the Company’s leverage profile. Under the terms of the agreement, CVG will lease back the Vonore property for a 20-year term, with an initial annual base rent of approximately $1.4 million for the first year.

“This transaction builds on our recent momentum, providing additional cash flow to deleverage,” said James Ray, President and Chief Executive Officer of CVG. “We continue to deliver on our previously stated objectives, with CVG’s near-term focus being on cash generation and lowering our debt levels. Following this transaction, we believe we are even better positioned to drive future growth and shareholder value at CVG.”

CVG anticipates no disruption to operational activities at the Vonore plant.

In conjunction with this announcement, CVG has reaffirmed its previously issued full-year 2026 outlook provided in its fourth-quarter 2025 earnings materials, released on March 10, 2026.

Company Contact
Michelle Hards
Vice President, Investor Relations and Corporate Financial Planning and Analysis
[email protected]

Investor Relations Contact
Ross Collins or Nathan Skown
Alpha IR Group
[email protected]

About CVG

CVG is a global provider of systems, assemblies and components to the global commercial vehicle market and the electric vehicle market. We deliver real solutions to complex design, engineering and manufacturing problems while creating positive change for our customers, industries and communities we serve. Information about the Company and its products is available on the internet at www.cvgrp.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. For this purpose, any statements contained herein that are not statements of historical fact, including without limitation, certain statements herein regarding industry outlook, the Company’s expectations for future periods with respect to its plans to improve financial results, the future of the Company’s end markets changes in the Class 8 and Class 5-7 North America truck build rates, performance of the global construction and agricultural equipment business, the Company’s prospects in the wire harness and electric vehicle markets, the Company’s initiatives to address customer needs, organic growth, the Company’s strategic plans and plans to focus on certain segments, competition faced by the Company, volatility in and disruption to the global economic environment, including global supply chain constraints, inflation and labor shortages, tariffs and counter-measures, financial covenant compliance, anticipated effects of acquisitions or divestitures, production of new products, plans for capital expenditures and our results of operations or financial position and liquidity, may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe”, “anticipate”, “plan”, “expect”, “intend”, “will”, “should”, “could”, “would”, “project”, “continue”, “likely”, and similar expressions, as they relate to us, are intended to identify forward-looking statements. The important factors discussed in “Item 1A – Risk Factors” in the Company’s Annual Report on Form 10-K, among others, could cause actual results to differ materially from those indicated by forward-looking statements made herein and presented elsewhere by management from time to time. Such forward-looking statements represent management’s current expectations and are inherently uncertain. Investors are warned that actual results may differ from management’s expectations. Additionally, various economic and competitive factors could cause actual results to differ materially from those discussed in such forward-looking statements, including, but not limited to, factors which are outside our control.

Any forward-looking statement that we make in this press release speaks only as of the date of such statement, and we undertake no obligation to update any forward-looking statement or to publicly announce the results of any revision to any of those statements to reflect future events or developments. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data.

Primary Logo

Source: Commercial Vehicle Group, Inc.